Ovid Therapeutics Inc. (OVID)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

2.1700

-0.0300

(-1.36%)

As of 03:46PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	2.2000
Open	2.2000
Bid	2.1600 x 1100
Ask	2.1800 x 1100
Day's Range	2.1400 - 2.2200
52 Week Range	1.6500 - 3.7800
Volume	93,978
Avg. Volume	174,954

Market Cap	152.81M
Beta (5Y Monthly)	1.23
PE Ratio (TTM)	N/A
EPS (TTM)	-0.9460
Earnings Date	Nov 08, 2022 - Nov 14, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	4.70

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

65% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for OVID

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Ovid Therapeutics Inc.
Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Rating
Fair Value
Economic Moat
16 days agoMorningstar

All

Simply Wall St.
Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
The big shareholder groups in Ovid Therapeutics Inc. ( NASDAQ:OVID ) have power over the company. Institutions will...
- Do Insiders Own Lots Of Shares In IronNet, Inc. (NYSE:IRNT)?
  Simply Wall St.
- Do Insiders Own Lots Of Shares In Diebold Nixdorf, Incorporated (NYSE:DBD)?
  Simply Wall St.
GlobeNewswire
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data from six animal models reinforcing the seizure-reducing potential of OV329 at two leading epilepsy research meetings Ended the second quarter 2022 with cash, cash equivalents and marketable securities of $152.4 million, expected to support the advancement of its epilepsy pipeline into 2025 NEW YORK, Au
Simply Wall St.
We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...